Cardiac cycle

UltraLinQ Launches New Wearable Holter Device with UbiqVue ECG Analysis and Interpretation Software

Retrieved on: 
Thursday, February 22, 2024
Cardiology, Sleep, Exercise, ECG, American Heart Month, PVC, Cardiac cycle, Arrhythmia, Patient, Workflow, Medical imaging

LONG ISLAND CITY, N.Y., Feb. 22, 2024 /PRNewswire/ -- Today, during American Heart Month, UltraLinQ is proud to announce the launch of its new Holter Program with the UbiqVue Holter and ECG Interpretation Software. This innovative biosensor comes with ECG analysis and interpretation software for uploading, interpreting, and managing ECG data and final reports. The Holter device and ECG interpretation software platform are designed to meet the intricate needs of modern cardiology practices, making excellent cardiac care seamless, accessible, and scalable.

Key Points: 
  • LONG ISLAND CITY, N.Y., Feb. 22, 2024 /PRNewswire/ -- Today, during American Heart Month, UltraLinQ is proud to announce the launch of its new Holter Program with the UbiqVue Holter and ECG Interpretation Software.
  • This innovative biosensor comes with ECG analysis and interpretation software for uploading, interpreting, and managing ECG data and final reports.
  • The Holter device and ECG interpretation software platform are designed to meet the intricate needs of modern cardiology practices, making excellent cardiac care seamless, accessible, and scalable.
  • Visit www.ultralinq.com/holter-service to learn more about adding UltraLinQ's Holter devices and advanced interpretation software to your practice or organization.

Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy

Retrieved on: 
Monday, October 9, 2023
Genetics, Clinical Trials, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Disease, Cardiac cycle, HIV disease progression rates, Arrhythmia, Rejuvenation, Research, Trial of the century, B cell, DSM-IV codes, MD, Liver, ACM, IND, Heart, Sudden death, Mutation, FDA, Heart failure, AAV, Gene, ARVC, Genetic disorder, PVC, DSP, SADS, Arrhythmogenic cardiomyopathy, Cardiac muscle, FGF21, Patient, Quality of life, Vaccine, Medical device, Pharmaceutical industry

Rejuvenate Bio , today announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key disease-mediating pathways.

Key Points: 
  • Rejuvenate Bio , today announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key disease-mediating pathways.
  • RJB-0402 demonstrated efficacy in a mouse model of arrhythmogenic cardiomyopathy (ACM), an inherited disease caused by mutations in one of several genes encoding desmosomal proteins.
  • “What makes RJB-0402 especially promising is its superior performance in the ACM nonclinical model, outperforming gene replacement therapies in reducing PVCs.
  • The initial clinical study for RJB-0402 will focus on patients with Desmoplakin-related arrhythmogenic cardiomyopathy (DSP ACM) at high risk of life-threatening ventricular arrhythmias and sudden cardiac death.

Live Long-Distance TeleRobotic Procedures to Highlight Stereotaxis Technology at Asia Pacific Heart Rhythm Symposium

Retrieved on: 
Wednesday, August 16, 2023
Cardiac cycle, Society, Atrial fibrillation, Hospital, MicroPort, Patient, Physician, Electrophysiology, Diagnosis, Cardiology, Congress, Robotics, NYSE, Medical device, Stereotaxis, EP

ST. LOUIS, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be the focus of multiple live long-distance telerobotic procedures at the upcoming Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions.

Key Points: 
  • ST. LOUIS, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be the focus of multiple live long-distance telerobotic procedures at the upcoming Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions.
  • APHRS and the Society for Cardiac Robotic Navigation will host a joint session on September 2, 2023, during the APHRS annual congress.
  • APHRS is the first society organized in the Asia Pacific region to promote excellence and advancement in the diagnosis and treatment of patients with heart rhythm disease.
  • They provide a platform for professional education, sharing of cutting-edge science, demonstration of advanced and novel techniques, and interaction among international experts in the field of heart rhythm management.

BIOTRONIK ANNOUNCED FIRST IMPLANT OF NEW IMPLANTABLE CARDIAC MONITOR WITH ARTIFICIAL INTELLIGENCE, TARGETING EFFICIENCY IN MONITORING FOR CARDIAC ARRHYTHMIAS

Retrieved on: 
Monday, June 12, 2023
Cardiac cycle, PVC, ICM, Intelligence, Doctor of Philosophy, Patient, EHR, Artificial intelligence, Diagnosis, PACS, AF, Health, Medical device, MD, Medicine

LAKE OSWEGO, Ore., June 12, 2023 /PRNewswire/ -- BIOTRONIK, a leader in implantable medical device technology, today announced the first global implantation of its BIOMONITOR IV implantable cardiac monitor (ICM). The procedure was conducted by Luigi Di Biase, MD, PhD, Section Head of Electrophysiology, Director of Arrhythmia Services and Professor of Medicine at Montefiore Einstein in the Bronx, NY. This first implant marks the next step in the advancement of cardiac monitoring technology.

Key Points: 
  • LAKE OSWEGO, Ore., June 12, 2023 /PRNewswire/ -- BIOTRONIK , a leader in implantable medical device technology, today announced the first global implantation of its BIOMONITOR IV implantable cardiac monitor (ICM).
  • This first implant marks the next step in the advancement of cardiac monitoring technology.
  • BIOMONITOR IV is a state-of-the-art ICM that pairs BIOTRONIK's SmartECG technology with artificial intelligence* to reduce all false positive detections by 86% while preserving 98% of true episodes1.
  • With this milestone, BIOTRONIK reinforces its position as a leading player in the field of cardiac monitoring devices, contributing to the advancement of cardiovascular medicine.

Cardiac Insight’s Cardea SOLO™ Wearable ECG System Chosen for Stanford Medicine Study to Measure Atrial Fibrillation in Older Women

Retrieved on: 
Thursday, January 5, 2023
Wearables, Mobile Technology, Technology, Medical Devices, Women, Seniors, Cardiology, Software, Health, Consumer, Insight, Algorithm, Stroke, Atrial fibrillation, Arrhythmia, Cardea, Research, Ventricular tachycardia, PPV, Cardiac cycle, Risk, Stanford University School of Medicine, Patient, ECG, AF, Data analysis, PACS, Bradycardia, Diagnosis, Positive, Medical imaging

Cardiac Insight, Inc., a leading healthcare innovator specializing in prescription-based wearable cardiac sensors and automated electrocardiogram (ECG) analysis software for cardiac arrhythmia diagnosis, today announced that researchers at Stanford Medicine selected the company’s Cardea SOLO™ wearable ECG system for a medical study entitled: Serial 7-Day Electrocardiogram Patch Screening for Atrial Fibrillation in High-Risk Older Women by the CHARGE-AF Score

Key Points: 
  • Cardiac Insight, Inc., a leading healthcare innovator specializing in prescription-based wearable cardiac sensors and automated electrocardiogram (ECG) analysis software for cardiac arrhythmia diagnosis, today announced that researchers at Stanford Medicine selected the company’s Cardea SOLO™ wearable ECG system for a medical study entitled: Serial 7-Day Electrocardiogram Patch Screening for Atrial Fibrillation in High-Risk Older Women by the CHARGE-AF Score
    The study set out to measure asymptomatic atrial fibrillation (AF) in older women since AF is associated with an increased risk of stroke.
  • The participants were mailed a Cardea SOLO ECG (electrocardiogram) patch monitor to be worn for seven days and returned for analysis.
  • The wearable ECG sensor provides exceptionally accurate results using Cardia Insight’s automated ECG data analysis and reporting software.
  • The Cardea SOLO disposable ECG biosensor has no cables and is comfortable and unobtrusive, encouraging patients to comply with prescribed wear times.

ITC Rules Apple Violated AliveCor's Patents

Retrieved on: 
Friday, December 23, 2022
Administrative law judge, Atrial fibrillation, SOC, United States International Trade Commission, Cardiac cycle, Wireless ambulatory ECG, Apple Watch, Patient, Arrhythmia, ECG, Apple Watch Series 4, Intellectual property, PTAB, Alivecor, ALJ, Patent, Stroke, HIPAA, Risk, FDA, Deep learning, Multimedia, ITC, LEO, Administrative law, Goliath, Sale, Certification, Patent Trial and Appeal Board, Ectopia, ISO, Generic drug, Medical device, Bradycardia, Apple, Tachycardia

MOUNTAIN VIEW, Calif., Dec. 22, 2022 /PRNewswire/ -- AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced that the International Trade Commission (ITC) has issued its Final Determination ruling that Apple Watch infringed AliveCor's patented technology. The ITC issued a Limited Exclusion Order (LEO), a cease and desist order and set a bond in the amount of $2.00 per unit of infringing Apple Watches imported or sold during the Presidential review period, potentially impacting sales of millions of infringing Apple Watches.

Key Points: 
  • The ITC issued a Limited Exclusion Order (LEO), a cease and desist order and set a bond in the amount of $2.00 per unit of infringing Apple Watches imported or sold during the Presidential review period, potentially impacting sales of millions of infringing Apple Watches.
  • The ITC has suspended enforcement of its orders pending resolution of AliveCor's appeal of the U.S. Patent and Trademark Office, Patent Trial and Appeal Board's ("PTAB") decision finding the asserted patents unpatentable.
  • Today's ruling marks a victory for AliveCor and affirms the Initial Determination issued in June by Administrative Law Judge (ALJ) Cameron Elliot of the ITC.
  • In addition to fighting Apple on patent infringement in the ITC, AliveCor continues to seek relief in the Northern District of California from Apple's anticompetitive behavior.

AliveCor's KardiaMobile Card Honored by the 2022 Fierce Life Sciences Innovation Awards and the 2023 CES® Innovation Awards

Retrieved on: 
Thursday, November 17, 2022
Alivecor, HIPAA, Atrial fibrillation, CTA, Arrhythmia, Certification, Deep learning, Senior, FDA, Consumer Technology Association, ISO, Sale, Multimedia, Patient, ECG, SOC, Stroke, The Economist, Cardiac cycle, Engineering, Global marketing, Digital health, Ectopia, Medical device, Bradycardia, Tachycardia

MOUNTAIN VIEW, Calif., Nov. 17, 2022 /PRNewswire/ -- AliveCor, the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced that KardiaMobile Card, the world's first credit-card-sized, FDA-cleared personal ECG device, has been named a 2022 Fierce Life Sciences Innovation Awards winner in the Medical Device Innovation category and a CES® 2023 Innovation Awards Honoree in the Digital Health category.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 17, 2022 /PRNewswire/ -- A liveCor , theleading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced that KardiaMobile Card, the world's first credit-card-sized, FDA-cleared personal ECG device, has been named a 2022 Fierce Life Sciences Innovation Awards winner in the Medical Device Innovation category and a CES 2023 Innovation Awards Honoree in the Digital Health category.
  • Introduced earlier this year, KardiaMobile Card is engineered to provide class-leading performance in the world's thinnest, lightest personal ECG.
  • The KardiaMobile Card is designed with convenience and durability in mind, helping patients manage their cardiac health anytime, anywhere.
  • The annual Fierce Life Sciences Innovation Awards, organized by Fierce Biotech and Fierce Pharma, identifies and highlights the latest and most impactful innovations in the life sciences industry across six categories.

BIOTRONIK Announces Collaboration with AliveCor As First In A Series of Strategic Partnerships to Disrupt Cardiac Digital Health With AI-Enabled Solutions

Retrieved on: 
Thursday, September 8, 2022
ISO, Partnership, ECG, Ectopia, Technology, Caregiver, Arrhythmia, AF2, Ohio State University Wexner Medical Center, Global Sales Law Project, Solution, AF, Decision-making, HIPAA, Sale, Heart, Incidence, EHR, Physician, Kannel, Diagnosis, Prognosis, Data management, SOC, Workflow, Deep learning, Health, FACC, Medicine, Stroke, FDA, Certification, Atrial fibrillation, Digital health, Cardiac cycle, Human body, Longevity, Patient, Medical device, Alivecor, FHRS, Bradycardia, Tachycardia, MD

LAKE OSWEGO, Ore., Sept. 8, 2022 /PRNewswire/ -- BIOTRONIK announced today its partnership with AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services. This partnership will combine the strengths of BIOTRONIK's BIOMONITOR Injectable Cardiac Monitor (designed with industry-leading 95.1% p-wave visibility1 across all cardiac cycles and 5.5 year longevity) with AliveCor's AI-enabled, clinically validated, medical-grade KardiaMobile 6L and KardiaMobile Card ECG technology. Through this pilot collaboration, healthcare providers will be able to access clinically relevant heart rhythm analyses and actionable reports to monitor at-risk patients; identify underlying arrhythmias, including atrial fibrillation (AF); and assess means to drive improvements to patient care and clinical outcomes.

Key Points: 
  • Up to 25% of stroke patients present with AF2, the most common type of treated cardiac arrhythmia.
  • Pairing AliveCor's KardiaMobile ECGs with BIOTRONIK's implantable device data strives to streamline workflow by providing comprehensive visibility within a single solution.
  • "Connecting wearable and implantable cardiac diagnostic device data from the earliest stages in the care continuum is groundbreaking," said Kenneth Nelson, Head of Digital Health and Diagnostics at BIOTRONIK.
  • This pilot collaboration is the first in a series of partnerships with leading digital health organizations to improve the delivery of connected care in cardiac diagnostics and remote patient monitoring.

AliveCor Announces Series F Financing to Help Expand Offerings to Key Healthcare Industry Stakeholders

Retrieved on: 
Tuesday, August 16, 2022
FDA, Multimedia, CVC, Risk, Health care, Atrial fibrillation, CEO, Qualcomm Ventures, Technology, Growth, Sale, ECG, Director, GE Healthcare, Board, Patient, Stroke, Ectopia, Certification, Khosla Ventures, Partnership, Cardiology, Deep learning, SOC, HIPAA, Privacy, Physician, Arrhythmia, ISO, Cardiac cycle, Hospital, Medical device, Tachycardia, Alivecor, Bradycardia

MOUNTAIN VIEW, Calif., Aug. 16, 2022 /PRNewswire/ -- AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced its Series F Financing led by GE Healthcare.

Key Points: 
  • MOUNTAIN VIEW, Calif., Aug. 16, 2022 /PRNewswire/ -- AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced its Series F Financing led by GE Healthcare.
  • These subscription services are supported by the company's personal ECG devices, including KardiaMobile, KardiaMobile 6L, and KardiaMobile Card.
  • This financing will also allow for continued advancements in AliveCor's AI roadmap and pipeline of innovations.
  • "This financing will help accelerate our growth into new strategic sectors and markets, enabling us to connect even more people to life-saving remote heart care."

Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy

Retrieved on: 
Tuesday, July 12, 2022
Cardiology, University, Biotechnology, Education, Other Health, Health, Pharmaceutical, Other Science, Research, Genetics, Science, Disease, Prevalence, U.S. Securities and Exchange Commission, Arrhythmogenic cardiomyopathy, AAV, Precision medicine, Arrhythmia, Communication, Student, Program, Education, Fisheries Research and Training Institute, Cardiac cycle, University of Utah, PVC, Muscle tissue, Company, Risk, School, RCOR, Patient, PKP2, COVID-19, Diagnosis, Heart failure, Private Securities Litigation Reform Act, DSG2, ACM, Securities & Exchange Commission of Pakistan, University, Genetics, Intellectual property, Invention, Degenerative disease, Forward-looking statement, DSP, Research, Ill, Quality of life, Growth, DCM, Person, NYSE, Pharmaceutical industry, Medicine

To accelerate this new program, Renovacor has entered into a research collaboration with the University of Utahs Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI).

Key Points: 
  • To accelerate this new program, Renovacor has entered into a research collaboration with the University of Utahs Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI).
  • The terms of the research agreement grant Renovacor an option for an exclusive license to inventions generated from the collaboration.
  • The research collaboration will focus on a protein discovered by University of Utah scientists that has the potential to address multiple genetic segments of ACM.
  • The program will be developed for the three largest genetic segments of ACM: plakophilin-2 (PKP2), desmoglein-2 (DSG2), and desmoplakin (DSP) associated ACM.